Tarsus pays $450M for Alkeus and its ph. 3 retinal disease drug

Tarsus Pharmaceuticals is acquiring Alkeus Pharmaceuticals for $450 million to gain rights to gildeuretinol, a phase 3-stage oral drug targeting Stargardt disease, a retinal condition with no current FDA-approved treatment. The acquisition complements Tarsus' existing ophthalmology portfolio and positions the company to potentially lead innovation in retinal disease therapies.

This Wire brief sits within Fusion42's coverage of Biotech.